New Criteria for Systemic Therapy Candidacy:
Description: New Criteria for Systemic Therapy Candidacy: Patients meeting one or more of the following criteria are candidates for systemic therapy: Psoriasis affecting 10 of Body Surface Area (BSA) Lesions on high-impact sites: Face, palms, soles,
Related Topics
Download Presentation
"New Criteria for Systemic Therapy Candidacy:" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. New Criteria for Systemic Therapy Candidacy:
Patients meeting one or more of the following criteria are candidates for systemic therapy:
Psoriasis affecting ≥10% of Body Surface Area (BSA)
Lesions on high-impact sites: Face, palms, soles, genitalia, scalp, and nails
Failure of topical therapies to control symptoms RECATEGORIZATION OF PSORIASIS SEVERITY
A GLOBAL CONSENSUS Overview: Clinical definitions of psoriasis severity are limited and do not fully reflect the disease’s real-world impact on patients’ quality of life. Traditional severity classifications often overlook critical factors, leaving many patients under-treated despite significant impairment. The International Psoriasis Council (IPC) sought to redefine these criteria to improve clinical decision-making. Key Findings The traditional “mild, moderate, severe” classification is overly simplistic and may not capture the true burden of the disease.
Quality of life impacts must be considered alongside clinical measures like PASI and BSA.
Systemic therapy should be accessible based on practical, patient-centered criteria rather than rigid thresholds. Conclusion and Future Directions Ongoing Research: Continued evaluation of severity criteria as new data emerge.
Call for Action: Adoption of the new consensus criteria in clinical practice to improve patient outcomes and standardize care globally. Impact and Meaning:
Why It Matters Broader Access to Treatments: Ensures more patients receive appropriate therapy, even if they don’t meet traditional PASI/BSA thresholds.
Patient-Centered: Considers quality-of-life impact beyond clinical scores.
Clinical Relevance: Aligns treatment decisions with the true burden of disease. International Psoriasis Council Board Members and Councilors. Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. Strober B, Ryan C, van de Kerkhof P, et al. J Am Acad Dermatol. 2020 Jan;82(1):117-122. doi: 10.1016/j.jaad.2019.08.026. Epub 2019 Aug 16. PMID: 31425723. Consensus Methodology
How It Was Done Approach: Modified Delphi method engaging international psoriasis experts.
Participants: IPC’s global network of dermatology specialists.
Process: Several rounds of structured discussions and voting to reach consensus on redefining severity criteria, aiming to create practical, patient-centered guidelines that enhance clinical decision-making.<br>
Patients meeting one or more of the following criteria are candidates for systemic therapy:
Psoriasis affecting ≥10% of Body Surface Area (BSA)
Lesions on high-impact sites: Face, palms, soles, genitalia, scalp, and nails
Failure of topical therapies to control symptoms RECATEGORIZATION OF PSORIASIS SEVERITY
A GLOBAL CONSENSUS Overview: Clinical definitions of psoriasis severity are limited and do not fully reflect the disease’s real-world impact on patients’ quality of life. Traditional severity classifications often overlook critical factors, leaving many patients under-treated despite significant impairment. The International Psoriasis Council (IPC) sought to redefine these criteria to improve clinical decision-making. Key Findings The traditional “mild, moderate, severe” classification is overly simplistic and may not capture the true burden of the disease.
Quality of life impacts must be considered alongside clinical measures like PASI and BSA.
Systemic therapy should be accessible based on practical, patient-centered criteria rather than rigid thresholds. Conclusion and Future Directions Ongoing Research: Continued evaluation of severity criteria as new data emerge.
Call for Action: Adoption of the new consensus criteria in clinical practice to improve patient outcomes and standardize care globally. Impact and Meaning:
Why It Matters Broader Access to Treatments: Ensures more patients receive appropriate therapy, even if they don’t meet traditional PASI/BSA thresholds.
Patient-Centered: Considers quality-of-life impact beyond clinical scores.
Clinical Relevance: Aligns treatment decisions with the true burden of disease. International Psoriasis Council Board Members and Councilors. Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. Strober B, Ryan C, van de Kerkhof P, et al. J Am Acad Dermatol. 2020 Jan;82(1):117-122. doi: 10.1016/j.jaad.2019.08.026. Epub 2019 Aug 16. PMID: 31425723. Consensus Methodology
How It Was Done Approach: Modified Delphi method engaging international psoriasis experts.
Participants: IPC’s global network of dermatology specialists.
Process: Several rounds of structured discussions and voting to reach consensus on redefining severity criteria, aiming to create practical, patient-centered guidelines that enhance clinical decision-making.<br>